Significant Funding Boost for Retinal Disease Research

In a promising development for the inherited retinal disease (IRD) community, Ollin Biosciences, a clinical-stage biotech company, has successfully closed an oversubscribed Series B financing round, raising $330 million. This substantial investment is earmarked to support the global Phase III clinical development of OLN324, a lead candidate for the treatment of diabetic macular edema (DME) and wet (neovascular) age-related macular degeneration (wAMD). This funding represents a significant step forward in the quest for new and improved therapies for vision-threatening conditions, offering renewed hope to patients and families affected by retinal diseases.

Key Facts from the Funding Announcement

Ollin Biosciences announced on June 24, 2026, that it secured $330 million in an oversubscribed Series B financing round. The funding will primarily be used to advance global Phase III studies for OLN324, a next-generation VEGF/Ang2 bispecific antibody. These late-stage trials for OLN324 in DME and wAMD are planned to begin in the second half of 2026. Ollin Biosciences has already completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and received scientific advice from the European Medicines Agency (EMA) regarding the Phase III program.

Earlier this year, Ollin Biosciences reported positive topline results from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®) in over 160 patients with DME or wAMD. In this study, OLN324 demonstrated faster and greater improvements in retinal anatomy and numerically greater vision gains compared to faricimab in DME. Specifically, in DME patients, OLN324 showed superior retinal drying and faster central subfield thickness (CST) improvements. In wAMD, OLN324 also showed rapid and comparable improvements in retinal drying and numerically greater vision gains. The financing will also support the advancement of OLN102, a novel TSHR/IGF-1R bispecific antibody for thyroid eye disease (TED) and Graves' disease, into clinical development this year.

What This Means for Patients and Families

For individuals living with or at risk of retinal diseases like DME and wAMD, this significant funding for Ollin Biosciences brings renewed hope. The progression of OLN324 into Phase III clinical trials means that a potential new treatment is moving closer to becoming available. Phase III trials are a critical step, involving larger patient populations to confirm the safety and efficacy of a new therapy.

The positive results from the earlier Phase 1b study, which indicated faster and greater improvements in retinal anatomy and vision compared to an existing treatment, are particularly encouraging. While these specific conditions (DME and wAMD) are distinct from many inherited retinal diseases, advancements in understanding and treating any retinal condition contribute to the broader field of ophthalmology. Success in these areas can often pave the way for research and development in other complex eye diseases, including IRDs.

Looking Ahead

With the initiation of global Phase III trials for OLN324 anticipated in the second half of 2026, the coming years will be crucial for evaluating its full potential. The IRD community will closely watch these developments, as innovative treatments for any form of vision loss hold the promise of improving the lives of countless individuals worldwide.